Endothelium-Dependent Hemostatic Factors in Women with Previous Gestational

Gestasyonel Diyabet Öyküsü Olan Hastalarda Endotel Bağımlı Hemostatik Faktörler

Tevfik Demir, Bânş Akıncı, Serkan Yener, Leyla Argun*, Mehmet Ali Öзcan**, Sevinç Eraslan
Dokuz Eylül University Faculty of Medicine, Department of Endocrinology and Metabolism, İzmir, Turkey
* Atatürk Training and Research Hospital, Clinic of Biochemistry, İzmir, Turkey
**Dokuz Eylül University Faculty of Medicine, Department of Hematology, İzmir, Turkey

Abstract

Purpose: Women with previous gestational diabetes mellitus (pGDM) are at increased risk for developing type 2 diabetes and cardiovascular disorders. The aim of this study was to investigate the levels of endothelium-dependent hemostatic factors in women with pGDM.

Material and Method: Eighty women with pGDM and 40 healthy women with no history of pGDM were included. The levels of glucose, insulin, c-peptide, lipids, C-reactive protein (CRP), and endothelium-dependent hemostatic factors, including plasminogen activator inhibitor-1 (PAI-1), von Willebrand factor, fibrinogen, tissue factor (TF), tissue plasminogen activator, and total tissue factor pathway inhibitor (TFPI), were measured.

Results: Women with pGDM had higher levels of CRP (p<0.001), fibrinogen (p=0.001), PAI-1 (p<0.001), TF (p=0.035), and total TFPI (p=0.009) compared to controls. Circulating levels of CRP and PAI-1 were significantly elevated in women with pGDM even after adjustment of body mass index (BMI) (CRP: p=0.022, and PAI-1: p=0.039). PAI-1 levels were positively correlated with BMI (r=0.374, p<0.001), waist-hip ratio (r=0.251, p=0.006), low density lipoprotein -cholesterol (r=0.246, p=0.007), triglyceride (r=0.296, p=0.001), fasting glucose (r=0.339, p<0.001), 2-h. plasma glucose (r=0.247, p=0.007), fasting insulin (r=0.334, p<0.001) and insulin resistance index (r=0.36, p<0.001), and negatively correlated with high-density lipoproteins-cholesterol (r=−0.420, p<0.001) and quantitative insulin sensitivity check index (r=−0.323, p<0.001).

Discussion: Our study shows that women with pGDM exhibit altered levels of endothelium-dependent hemostatic factors which seem to be associated with cardiovascular risk factors.

Keywords: Previous gestational diabetes, endothelium-dependent hemostatic factors, cardiovascular risk factors

Address for Correspondence: Tevfik Demir MD, Dokuz Eylül University Faculty of Medicine, Department of Endocrinology and Metabolism, İzmir, Turkey
E-mail: tevfikalper@gmail.com
Received: 04/01/2016
Accepted: 15/01/2016

Turkish Journal of Endocrinology and Metabolism, published by Galenos Publishing
Introduction

Previous gestational diabetes mellitus (pGDM) is associated with an increased risk for developing type 2 diabetes mellitus (DM). Previous studies have shown that women with pGDM feature cardiovascular risk markers, such as obesity, insulin resistance, subclinical inflammation, and endothelial dysfunction (1,2). Endothelial dysfunction is a key event in the development of atherosclerosis. Researchers have studied markers of endothelial function to determine the particular risk of developing atherosclerosis in selected populations (3,4,5,6). The levels of these markers are found to be associated with early stage of atherosclerosis which was considered by non-invasive assessments, such as ultrasonography of the carotid artery, namely by measuring carotid intima media thickness, and ankle-arm index in apparently healthy people with certain cardiovascular risk factors (7,8,9). It has been shown in previous studies that fibrinolytic malfunction leads to atherosclerosis in patients with insulin-resistance. Once the coagulation system gets activated, tissue factor and factor FVIIa generate thrombin. The next step is the conversion of fibrinogen to fibrin. This is followed by adaptive mechanisms, such as plasmin-mediated fibrinolysis that is triggered by the activation of plasminogen to plasmin which is catalyzed by tissue-type plasminogen activator (t-PA). Fibrinolysis, in turn, solubilizes the fibrin structures that one can call clot lysis. This process ends up with the formation of fibrin degradation products. There are some inhibitors of this fibrinolytic process. Plasminogen activator inhibitor-1 (PAI-1) is the most significant inhibitor of this system that works by reducing the activity of fibrinolysis mainly by putting an inhibitory signal on t-PA. As a result, thrombosis is promoted by decreased fibrinolytic activity which is maintained by the suppressed activation of plasminogen caused by elevated levels of PAI-1 (10).

Previous studies have suggested that insulin resistance modulates circulating levels of the coagulation factors. It has been also shown that the levels of these markers are correlated with inflammation, as determined by the sensitive inflammatory marker C-reactive protein (CRP) (11). In this study, we aimed to investigate the levels of endothelium-dependent hemostatic factors total tissue factor pathway inhibitor (TFPI), tissue factor (TF), von Willebrand factor (vWF), t-PA, and PAI-1 as well as the parameters of endothelial function and inflammation CRP in women with pGDM.

Materials and Methods

Ninety patients with pGDM and 40 age-matched controls were enrolled. Gestational diabetes mellitus (GDM) was diagnosed according to the modified Carpenter and Coustan criteria (12). Healthy controls were selected from hospital staff without any known diseases. Controls had a 1-hour glucose value of less than 140 mg/dL after a 50-g glucose challenge test during their pregnancy, and were defined as having normal glucose tolerance. Women with DM, thyroid dysfunction, severe chronic kidney disease or liver disease and those on chronic medication known to influence carbohydrate metabolism or hemostasis were excluded. Among 90 women with pGDM, 10 were excluded as they were diagnosed with type 2 DM after a 75-g oral glucose tolerance test (OGTT). The study was approved by the institutional Ethics Committee of Dokuz Eylul University. All subjects gave written informed consent. All subjects were evaluated after 10 hours fasting. Weight, height, and waist circumference were measured. Height was recorded to the nearest 0.5 cm, and weight was measured to the nearest 0.1 kg. Body mass index (BMI) was calculated as weight/height² (kg/m²). Girth measurements were estimated as the average of duplicate measures. Waist circumference (WC) was measured from the mid-level between the iliac crest and the lowest rib, and the hip circumference at the trochanter major level to the nearest 0.5 cm. Foot-to-foot body fat analyzer (ITBF-300, Tanita Body Composition Analyzer, Germany) was used for bioelectrical impedance analysis. Total body water (TBW), fat-free mass, fat mass (FM) and fat percentage (%) were recorded. Blood was drawn between 8:00 am and 9:00 am at fasting. Blood samples were transferred into tubes containing fluoride for plasma glucose assay, buffered citrate for hemostatic markers, and tubes suitable for serum separation. Samples were centrifuged for a minimum 10 min at 3,000 g. Aliquots were frozen at -80 °C until the time of assay.

Glucose was measured by the hexokinase method (Hitchichi, Tokyo, Japan). Lipids were measured by enzymatic reactions (Hitchi, Tokyo, Japan). Insulin and C-peptide were measured by a chemiluminescent immunoassay (Immulite 1000, DPC, USA). The quantitative insulin-sensitivity check index (QUICKI) (13) and homeostasis model assessment for insulin resistance (HOMA-IR) (14) were calculated as defined previously. CRP was measured by an immunoturbidimetric assay (Cobas Integra 400-Roche Diagnostics; Behring Fibrintimer, IL, US). Fibrinogen and D-dimer were measured using the Clauss method (Dade Behring Diagnostics; Behring Fibrinimter, IL, US). PAI-1, TF, vWF, IPA and TFPI were measured using ELISA (American Diagnostica Inc., Stanford, CT, US).

The sample size was calculated prior to study using the Power and Precision software (version 2, 2000, Biostat, Englewood, NJ, US). Data are presented as means ± standard deviation. The Kolmogorov-Smirnov test was used for assessment of variable distribution. Continuous variables were compared by the independent t-test. Chi-square test was used for comparison of categorical variables. Correlation analysis was conducted by using Spearman’s correlation coefficient. To avoid confounding factors, such as the effect of BMI on studied parameters, partial correlation analysis was performed. Statistical significance was defined as a two-sided p value of <0.05. The statistical analysis was performed by Statistical Package of Social Science (SPSS), version 15.0.

Results

The characteristics of subjects are presented in Table 1. Women with pGDM and healthy controls did not differ in means of age, postpartum duration and smoking habits. As expected, BMI, waist-hip ratio (WHR), body fat percentage and FM were higher in women with pGDM. Twenty-three (28.7%) women in the pGDM
group had impaired glucose tolerance (IGT) and twelve (15%) women in the pGDM group had hypertension. Fifty-five (68.8%) women with pGDM had a family history of DM. Women with pGDM had higher fasting glucose, postprandial glucose, total cholesterol, LDL-cholesterol and triglyceride levels than controls. Fasting insulin and C-peptide levels and HOMA-IR scores were higher in the pGDM group. Women with pGDM had decreased HDL-cholesterol (p=0.03) and QUICKI score (Table 1). Compared to control group, women with pGDM had higher levels of CRP, fibrinogen, PAI-1, TF, and TFPI (Table 2). After adjusting BMI, CRP (p=0.022) and PAI-1 (p=0.039) remained higher in women with pGDM. PAI-1 levels were correlated with BMI (r=0.374, p<0.001), WHR (r=0.25), p=0.006), LDL-cholesterol (r=0.246, p=0.007), triglyceride (r=0.296, p=0.001), HDL-cholesterol (r=-0.42, p<0.001), fasting glucose (r=0.339, p<0.001), 2-h. plasma glucose (r=0.247, p=0.007), triglyceride (r=0.296, p=0.001), HDL-cholesterol (r=-0.42, p<0.001), fasting glucose (r=0.339, p<0.001), 2-h. plasma glucose (r=0.247, p=0.007), insulin (r=0.334, p<0.001), HOMA-IR (r=0.36, p<0.001), QUICKI (r=-0.323, p<0.001), CRP (r=0.272, p=0.004), and TF (r=0.235, p=0.011) in the whole group.

**Discussion**

Increased levels of endothelium-dependent hemostatic factors may be associated with increased cardiovascular risk in women with pGDM (15,16,17,18). Increased levels of CRP, a marker of subclinical inflammation, have been reported in pregnancy complicated by GDM and also in women with pGDM (19,20,21,22). Exalted plasma PAI-1 level is the key feature of insulin resistance (23,24). There are numerous studies reporting elevated levels of PAI-1 in type 2 DM (25) as well as in non-diabetic overweight and obese individuals (26,27) and those with metabolic syndrome (28). Plasma concentration of PAI-1 has previously been used as a surrogate marker of endothelial damage (5,29). As previously shown, increased levels of PAI-1 in women with pGDM could result from tissue cytokine disturbances. Increased amounts of intraabdominal adipose tissue contribute directly to the pathogenesis of subclinical inflammation, insulin resistance and endothelial dysfunction (30).

Women with pGDM had insulin resistance, obesity, dyslipidemia and elevated plasma levels of endothelium-dependent hemostatic factors compared to healthy controls. A significant number of women with pGDM displayed classical features of metabolic syndrome. In the present study, we studied a group of women with pGDM, a population known to be at increased risk of developing type 2 DM (31,32).

Our data showed that levels of TFPI (another marker of endothelial disturbance) were elevated in the pGDM group. To the best of our knowledge, this is the first study showing that TFPI is increased in women with pGDM. TFPI is a vascular anticoagulant that can cause an inhibition in the tissue factor associated steps of coagulation. TFPI is mainly synthesized in the endothelial cells, but the mechanisms by which TFPI is bound to and released from the endothelial cells have not been entirely elucidated (33). It has been shown that elevated TFPI is associated with endothelial dysfunction in diabetic patients with coronary heart disease, and speculated to be an indicator of subclinical atherosclerosis (6,18,34). In a previous study, Sakkinen et al. (35) have reported that plasma TFPI activity positively correlated with subclinical atherosclerosis in people with no known disorder. Sakata et al. (8) showed that TFPI levels were associated with carotid intima media thickness, an indicator of endothelial dysfunction.

In pGDM women without any traditional cardiovascular risk factors (such as obesity, hyperlipidemia, hypertension and

### Table 1. Clinical characteristics and metabolic parameters of women with previous gestational diabetes mellitus and healthy controls

| Parameter                  | pGDM (n=80) | Control (n=40) | p   |
|----------------------------|------------|---------------|-----|
| Age (year)                 | 36±6       | 34±4          | 0.106 |
| Years postpartum           | 3.2±4.6    | 4.3±3.6       | 0.170 |
| BMI (kg/m²)                | 28.3±6.5   | 22.7±2.6      | <0.001 |
| WHR                        | 0.86±0.07  | 0.78±0.05     | <0.001 |
| Fat %                      | 34.7±8.5   | 26.9±6.4      | <0.001 |
| Fat mass                   | 26.3±12.0  | 16.5±5.6      | <0.001 |
| Smoking (packet/year)      | 0.9±2.2    | 1.2±2.5       | 0.543 |
| Fasting glucose (mg/dL)    | 89.3±11.5  | 78.1±9.2      | <0.001 |
| 2-hour plasma glucose (mg/dL) | 115.9±30.6 | 82.6±14.8     | <0.001 |
| Insulin (µU/mL)            | 13.7±11.9  | 7.0±3.9       | <0.001 |
| HOMA-IR                    | 3.1±2.6    | 1.3±0.8       | <0.001 |
| QUICKI                     | 0.3±0.30   | 0.4±0.04      | <0.001 |
| Total cholesterol (mg/dL)  | 188.7±40.1 | 169.3±27.9    | 0.003 |
| LDL cholesterol (mg/dL)    | 105.1±31.2 | 90.1±23.7     | 0.008 |
| HDL cholesterol (mg/dL)    | 58.8±17.1  | 66.1±17.2     | 0.030 |
| Triglycerides (mg/dL)      | 128.2±113.7| 79.9±29.5     | 0.001 |

Table 1. Clinical characteristics and metabolic parameters of women with previous gestational diabetes mellitus and healthy controls

| Parameter                  | pGDM (n=80) | Control (n=40) | p   |
|----------------------------|------------|---------------|-----|
| CRP                        | 3.6±3.5    | 1.2±1.1       | <0.001 |
| Fibrinogen                 | 4.1±1.1    | 3.4±0.7       | 0.001 |
| D-dimer                    | 218.4±103.8| 213.5±89.7    | 0.803 |
| PAI-1                      | 43.1±19.5  | 28.5±13.8     | <0.001 |
| vWF                        | 100.4±36.3 | 96.7±35.6     | 0.596 |
| TF                         | 123.7±88.4 | 91.4±50.5     | 0.035 |
| t-PA                       | 5.8±4.5    | 6.4±5.8       | 0.554 |
| Total TFPI                 | 49.0±26.8  | 39.9±9.9      | 0.009 |

Table 2. The comparison of endothelium dependent hemostatic factors and inflammatory markers in women with previous gestational diabetes mellitus and healthy controls

**pGDM**: Previous gestational diabetes mellitus, BMI: Body mass index, WHR: Waist-hip ratio, HOMA-IR: Homeostasis model assessment for insulin resistance, QUICKI: Quantitative insulin-sensitivity check index, LDL: Low density lipoprotein, HDL: High density lipoprotein, Data are presented as mean ± standard deviation
impaired glucose tolerance), we found higher levels of CRP, fibrinogen, PAI-1 and TF. Our data suggests that a low-grade inflammation state and endothelial dysfunction could be present independently of other cardiovascular risk factors in women with previous GDM. This finding is in line with a study by Di Cianni et al. [20], where they found higher CRP values in pGDM women without metabolic syndrome. Our findings may be partly explained by the presence of central obesity in women with pGDM. We should note that WHR was different between the subgroup of women with pGDM, who had no traditional cardiovascular risk factor, and healthy controls. Pannacciuilli et al. [36] reported that total adiposity, central fat, and insulin resistance were the main determinants of plasma PAI-1 concentrations in the presence of normal glucose tolerance, as we observed in the present study. As previously shown, increased PAI-1 expression in subjects with pGDM could result from tissue cytokine disturbances, such as elevated transforming growth factor-beta-1 (TGF-β1) expression [37]. TGF-β1 has been shown to be expressed in the adipose tissue, where it up-regulates the production of PAI-1 [38]. Visceral adiposity is associated with insulin resistance, and it is one of the main factors contributing to the development of atherosclerosis.

Our study had several limitations. First, we did not exclude women who were at lactation period. It is not known if lactation has any effect on the levels of endothelium-dependent hemostatic factors. Second, insulin resistance was assessed by HOMA-IR in our study. No insulin clamp study was performed. Third, central obesity was evaluated by waist circumference and WHR. No imaging studies were performed.

**Conclusion**

Women with pGDM had increased levels of endothelium-dependent hemostatic factors which may contribute to increased cardiovascular risk. Women with pGDM had higher levels of CRP, fibrinogen, PAI-1, and TF. Our data showed that levels of TFPI (another marker of endothelial disturbance) were elevated in women with pGDM. PAI-1 levels were positively correlated with BMI, WHR, LDL-cholesterol, triglyceride, fasting glucose, 2-hour plasma glucose, fasting insulin and HOMA-IR, and negatively correlated with HD-cholesterol and QUICKI index. Even in pGDM women without any traditional cardiovascular risk factors (such as obesity, hyperlipidemia, hypertension and impaired glucose tolerance, levels of CRP, fibrinogen, PAI-1 and TF were elevated. Our data suggest that a low-grade inflammation state and endothelial dysfunction could be present independently of other cardiovascular risk factors in women with pGDM.

**Ethics**

**Ethics Committee Approval:** The study was approved by the institutional Ethics Committee of Dokuz Eylül University. **Informed Consent:** It was taken. **Peer-review:** Externally peer-reviewed.

**Authorship Contributions**

**Surgical and Medical Practices:** Tevfik Demir, Barış Akıncı, Serkan Yener, Leyla Argun, Mehmet Ali Özcan, Sevinç Eraslan, **Concept:** Tevfik Demir, Barış Akıncı, Serkan Yener, **Design:** Tevfik Demir, Sevinç Eraslan, **Data Collection or Processing:** Tevfik Demir, Barış Akıncı, Serkan Yener, Leyla Argun, **Analysis or Interpretation:** Tevfik Demir, Barış Akıncı, Serkan Yener, Leyla Argun, **Literature Search:** Tevfik Demir, **Writing:** Tevfik Demir.

**Conflict of Interest:** No conflict of interest was declared by the authors.

**Financial Disclosure:** The authors declared that this study received no financial support.

**References**

1. Winzer C, Wagner O, Festa A, Schneider B, Roden M, Bancher-Todesca D, Pocini G, Funahashi T, Kadowaki-Yi A. Plasma adiponectin, insulin sensitivity, and subclinical inflammation in women with prior gestational diabetes mellitus. Diabetes Care 2004;27:1721-1727.

2. Lauenborg J, Mathiesen E, Hansen T, Glümer C, Ægner T, Borch-Johnsen K, Hornnes P, Pedersen O, Dammt P. The prevalence of the metabolic syndrome in a Danish population of women with previous gestational diabetes mellitus is three-fold higher than in the general population. J Clin Endocrinol Metab 2005;90:4004-4010.

3. Thøgersen AM, Janssens JH, Boman K, Nilsson TK, Weinerh L, Hultasafar F, Hollmans G. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998;98:2241-2247.

4. Lee AJ, MacGregor AS, Hau CM, Price JF, Rumley A, Lowe GD, Foxkhes FG. The role of haematological factors in diabetic peripheral arterial disease: the Edinburgh artery study. Br J Haematol 1999;105:648-654.

5. Meigs JB, O‘Donnell C, Toffler GH, Benjamin EJ, Fox CS, Liptskis I, Nathan DM, Sullivan LM, D’Agostino RB, Wilson PW. Hemostatic markers of endothelial dysfunction and risk of incident type 2 diabetes: the Framingham Offspring Study. Diabetes 2006;55:530-537.

6. Morange PE, Renucci JF, Charles MA, Aillaud MF, Giraud F, Grimaux M, Junan-Vauge I. Plasma levels of free and total TFPI, relationship with cardiovascular risk factors and endothelial cell markers. Thromb Haemost 2001;85:999-1003.

7. Kalhresan S, Gona P, Larson MG, Vita JA, Mitchell GH, Toffler GH, Levy D, Newton-Cho M, Wang AJ, Benjamin EJ, Vasan R. Cross-sectional relations of multiple biomarkers from distinct biological pathways to brachial artery endothelial function. Circulation 2006;113:938-945.

8. Sakata T, Mannami T, Baba S, Kobu Y, Kario K, Okamoto A, Kameda K, Ohkura N, Katayama Y, Miyata T, Tomoihe K, Kato H. Potential of free-form TFPI and PAI-1 to be useful markers of early atherosclerosis in a Japanese general population (the Suita Study): association with the intimal-medial thickness of carotid arteries. Atherosclerosis 2004;176:355-360.

9. Lee KW, Blann AD, Lip GY. Inter-relationships of indices of endothelial damage/dysfunction (circulating endothelial cells, von Willebrand factor and flow-mediated dilatation) to tissue factor and interleukin-6 in acute coronary syndromes. Int J Cardiol 2006;111:302-308.

10. Bloedberg EM, Madson JS, Kristenssen SR, Abrahamsson B, Brixen K, Moskalel L, Jespersen F. Effect of long-term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study. J Thromb Haemost 2003;1:1208-1214.

11. Havercate F. Levels of haemostatic factors, arteriosclerosis and cardiovascular disease. Vasc Pharmacol 2002;39:109-112.

12. Metzger BE, Coustan DR. Summary and recommendations of the Fourth International Workshop-Conference on Gestational Diabetes Mellitus. The Organizing Committee. Diabetes Care 1998;21(Suppl 2):161-167.

13. Katz A, Namb SS, Matter K, Baron AD, Foillmann DA, Sullivan G, Quon M. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000;85:2402-2410.
14. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.

15. Ridker PM. High-sensitivity C-reactive protein: Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001;103:1813-1818.

16. Festa A, D'Agostino R Jr, Howard G, Mykkänen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000;102:42-47.

17. Leurs PB, Stolk RP, Harnlyak K, Van Oerle R, Grobbee DE, Wofflenbuttel BH. Tissue factor pathway inhibitor and other endothelium-dependent hemostatic factors in elderly individuals with normal or impaired glucose tolerance and type 2 diabetes. Diabetes Care 2002;25:1340-1345.

18. Herman MP, Sukhova GK, Kisiel W, Foster D, Kehry MR, Libby P, Schönbeck U. Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis. J Clin Invest 2001;107:1117-1126.

19. Di Benedetto A, Russo GT, Corrado F, Di Cesare E, Alessi E, Nicocia G, D'Anna R, Cucinotta D. Inflammatory markers in women with a recent history of gestational diabetes mellitus. J Endocrinol Invest 2005;28:34-38.

20. Di Cianni G, Lencioni C, Volpe L, Ghio A, Cucciuri L, Pellegrini G, Benzi L, Miccoli R, Del Prato S. C-reactive protein and metabolic syndrome in non-obese type 2 diabetic patients. Diabetes Metab Res Clin Pract 2007;23:135-140.

21. Wolf M, Sandler L, Hsu K, Vossen-Smirnaks K, Ecker JL, Thadhani R. First-trimester C-reactive protein and subsequent gestational diabetes. Diabetes Care 2003;26:819-824.

22. Pradhan AD, Cook NR, Buring JE, Manson JE, Ridker PM. C-reactive protein is independently associated with fasting insulin in nondiabetic women. Arterioscler Thromb Vasc Biol 2002;22:2099-2104.

23. Metzger BE, Cho NH, Roston SM, Radvany R. Prepregnancy weight and antepartum insulin secretion predict glucose tolerance five years after gestational diabetes mellitus. Diabetes Care 1993;16:1598-1605.

24. Kaufmann RC, Schleyhahn FT, Huffman DG, Amankwah KS. Hemostatic factors and gestational diabetes diagnostic criteria: long-term maternal follow-up. Am J Obstet Gynecol 1995;172:621-625.

25. Mast AE, Aehara N, Malecha MJ, Hall CL, Dietzen DJ. Characterization of the association of tissue factor pathway inhibitor with human placenta. Arterioscler Thromb Vasc Biol 2002;22:1340-1344.

26. Mertens L, Considine RV, Van der Planken M, Van Gaal LF. Hemostasis and fibrinolysis in non-diabetic overweight and obese men and women. Is there still a role for leptin? Eur J Endocrinol 2006;155:477-484.

27. Romano U. Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis. J Clin Invest 2001;107:1117-1126.

28. Demir et al. Hemostatic Factors and Gestational Diabetes Mellitus 2016;20:43-47